Rockefeller Capital Management L.P. Trims Stock Holdings in IQVIA Holdings Inc. $IQV

Rockefeller Capital Management L.P. lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 76.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 67,847 shares of the medical research company’s stock after selling 216,570 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in IQVIA were worth $10,692,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Clal Insurance Enterprises Holdings Ltd grew its holdings in shares of IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after buying an additional 131 shares in the last quarter. Trust Co. of Toledo NA OH acquired a new stake in IQVIA during the second quarter worth approximately $39,000. J.Safra Asset Management Corp grew its stake in IQVIA by 208.6% in the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after acquiring an additional 169 shares during the period. NewSquare Capital LLC raised its holdings in IQVIA by 185.3% in the 2nd quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 189 shares during the last quarter. Finally, Atticus Wealth Management LLC purchased a new position in shares of IQVIA during the 2nd quarter worth $52,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on IQV shares. TD Cowen lowered IQVIA from a “buy” rating to a “hold” rating and upped their target price for the company from $206.00 to $215.00 in a research note on Monday, November 3rd. Citigroup lifted their price target on IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a report on Wednesday, October 29th. Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and upped their price target for the stock from $195.00 to $235.00 in a research report on Thursday, October 9th. Finally, Stifel Nicolaus boosted their price objective on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $240.61.

IQVIA Trading Up 0.1%

Shares of IQV stock opened at $217.50 on Thursday. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $228.12. The firm’s 50 day moving average price is $204.51 and its two-hundred day moving average price is $180.05. The stock has a market cap of $37.04 billion, a price-to-earnings ratio of 29.84, a price-to-earnings-growth ratio of 2.44 and a beta of 1.34.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter last year, the firm posted $2.84 EPS. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.